Download PDF

1. Company Snapshot

1.a. Company Description

Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide.It operates in two divisions, Photonics and Medical.The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement.


Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors.The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment.The company was founded in 1970 and is headquartered in Lannion, France.

Show Full description

1.b. Last Insights on LBIRD

Lumibird SA's recent momentum stems from shifting market sentiment. Although no major announcements were made, subtle moves in its share price have triggered a fresh look at its valuation. The company's steady gains have caught investors' attention, sparking questions about its growth potential. With no obvious catalyst, the recent uptick may signal an underappreciated story coming to light. Investors are reassessing their thesis on the stock, driven by long-term growth and profitability trends.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

3. NewsRoom

Card image cap

Europe Photodynamic Therapy Market Size, Trends, Leading Applications and Pricing Benchmarks (2025-2033) Featuring Gladerma, Sun Pharmaceutical, Biofrontera, Lumibird, Bausch Health Companies and More

Oct -31

Card image cap

3 European Stocks Estimated To Be Up To 36.2% Below Intrinsic Value

Oct -17

Card image cap

3 European Stocks Estimated To Be Up To 45.3% Below Intrinsic Value

Sep -10

Card image cap

Societe Generale: shares & voting rights as of 31 August 2025

Sep -09

Card image cap

Assessing Acciona (BME:ANA)'s Valuation After Recent Subtle Moves

Sep -09

Card image cap

Deutsche Bank (XTRA:DBK): Assessing Valuation After a Period of Quiet Share Price Momentum

Sep -09

Card image cap

Is Vaisala (HLSE:VAIAS) Undervalued? A Fresh Look at Its Current Valuation

Sep -09

Card image cap

Has Evotec’s 29.5% Price Drop Created a New Opportunity for 2025?

Sep -09

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.01%)

6. Segments

Medical

Expected Growth: 9%

Lumibird SA's Medical segment growth is driven by increasing demand for ophthalmology and medical imaging applications, advancements in laser technology, and strategic acquisitions. The company's focus on innovation, expanding product portfolio, and strong distribution network also contribute to its 9% growth rate.

Photonics

Expected Growth: 7%

Lumibird SA's Photonics segment growth is driven by increasing demand for high-power laser diodes in industrial and medical applications, as well as growing adoption of fiber lasers in material processing and microelectronics manufacturing. Additionally, advancements in quantum technology and LiDAR applications are expected to fuel further growth.

7. Detailed Products

Laser Diodes

High-power laser diodes for industrial, medical, and aerospace applications

Q-Switched Lasers

High-energy pulsed lasers for material processing, medical, and defense applications

Tunable Lasers

Wavelength-tunable lasers for spectroscopy, sensing, and metrology applications

Fiber Lasers

High-power fiber lasers for material processing, medical, and industrial applications

Ultrafast Lasers

High-intensity, ultra-short pulse lasers for material processing, spectroscopy, and microscopy

Laser Systems

Customized laser systems for industrial, medical, and scientific applications

8. Lumibird SA's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Lumibird SA is moderate due to the presence of alternative technologies and products in the market.

Bargaining Power Of Customers

The bargaining power of customers is low for Lumibird SA due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate for Lumibird SA due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants is high for Lumibird SA due to the low barriers to entry in the market and the presence of new technologies.

Intensity Of Rivalry

The intensity of rivalry is high for Lumibird SA due to the presence of several established competitors in the market.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 41.66%
Debt Cost 3.95%
Equity Weight 58.34%
Equity Cost 10.09%
WACC 7.53%
Leverage 71.41%

11. Quality Control: Lumibird SA passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Clínica Baviera

A-Score: 6.9/10

Value: 4.1

Growth: 8.2

Quality: 8.4

Yield: 7.5

Momentum: 7.0

Volatility: 6.3

1-Year Total Return ->

Stock-Card
Lumibird

A-Score: 3.7/10

Value: 2.3

Growth: 5.4

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

Stock-Card
Centogene

A-Score: 3.5/10

Value: 10.0

Growth: 1.4

Quality: 5.5

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

Stock-Card
Vimian Group

A-Score: 2.9/10

Value: 2.1

Growth: 7.2

Quality: 5.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

Stock-Card
Mainz Biomed

A-Score: 2.6/10

Value: 8.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Stock-Card
Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

20.6$

Current Price

20.6$

Potential

-0.00%

Expected Cash-Flows